PHILADELPHIA--(BUSINESS WIRE)--March 21, 2006--PolyMedix, Inc. announced today that it has received almost $3 million in a Phase II SBIR grant from the National Institutes of Health (NIH) for the continued development of its novel antibiotic drugs. The Advanced Technology grant entitled “Therapeutic Development of Antimicrobial Biomimetics,” was awarded by the NIH’s National Institute of Allergy and Infectious Disease (NIAID) and reflects the recognition of the company’s successful completion of its previously awarded Phase I grant.
